The deal suggests Roche sees substantial promise in Poseida’s technology, as the offer is 215% above the biotech’s closing ...

Shares in Amgen fell by double digits Tuesday on long-awaited results for the company’s monthly MariTide shot, which is ...

Patsnap, a global leader in innovation and pharma intelligence, announced the launch of Hiro Life Sciences (Hiro LS), a groundbreaking AI assistant poised to redefine biopharmaceutical research and ...

The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align resources” with its strategic priorities.

The setback likely removes one competitor to an emerging spinal muscular atrophy medicine from Scholar Rock, but sets the ...

Roche’s long-running bet on a new kind of cancer immunotherapy has, after years of shrinking optimism and second-guessing by ...

Reduced Weight Regain: CCT-217 shows promise in preventing weight regain commonly observed after discontinuing incretin ...

The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...

Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to ...

In buying Westlake-backed Kate Therapeutics, Novartis gets a handful of preclinical gene therapies targeting diseases like ...

The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...

The startup, Pep2Tango, is combining four methods of accelerating weight loss into one medicine in the hopes of developing a ...